Overview

This is a prospective observational study to identify biomarkers in parkinson syndromes. Patients with parkinsonian syndromes at the early stages of disease will be recruited and will be followed up until their established clinical diagnosis or for at least 5 years. In this population, imaging and wet biomarkers as well as clinical data will b systematically collected.

Eligibility

IΙnclusion Criteria:

• Written informed consent, including consent to monitoring
• Patients with Parkinsonism and disease duration < 2 years
• Patients with Parkinsonism and disease duration > 2 years
• Healthy individuals without any neurological disease

Exclusion Criteria:

• Drug-induced parkinsonism (eg, neuroleptics, lithium, valproic acid, metoclopramide).
• Metabolic conditions related parkinsonism (eg, Wilson's disease, hypoparathyroidism).
• Structural lesions on brain magnetic resonance imaging (MRI) that explain the symptoms, such as normal pressure hydrocephalus, moderate to severe chronic vascular encephalopathy, cerebral infarction, neoplasm
• Other serious diseases that indicate a life expectancy of <5 years.
• Active participation in other interventional clinical studies